Paper · 41701164

Mutation of rearranged during transfection (RET) is associated with enhanced tumor immunogenicity and favorable outcomes in pan-cancer immunotherapy.

Cai J and 7 others. Oncologist, 2026. Cited by 0 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. Mutation of rearranged during transfection (RET) is associated with enhanced tumor immunogenicity and favorable outcomes in pan-cancer immunotherapy. Papers, record 41701164. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41701164

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: Mutation of rearranged during transfection (RET) is associated with enhanced tumor immunogenicity and favorable outcomes in pan-cancer immunotherapy.; PubMed
Journal: Oncologist; PubMed
Year: 2026; PubMed
Publication types: Journal Article; PubMed
PubMed: https://pubmed.ncbi.nlm.nih.gov/41701164/; PubMed
DOI: https://doi.org/10.1093/oncolo/oyag049; PubMed
PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC12986760/; PubMed
The journal: https://conductscience.org/library/journal-index/9607837; PubMed
Citations, by iCite: 0; iCite
Revised in PubMed: 2026-08-13; PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename	ORCID iD
1	Cai J	Jingshuang
2	Huang Z	Zhiyang
3	Li Y	Yingying
4	Zhou J	Jin
5	Xu Y	Yingzhi
6	Cai M	Mingzhen
7	Zhao H	Hong
8	Zhao B	Bin	https://orcid.org/0000-0002-5990-1773

Source PubMed

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH term	Major
Neoplasms	Major topic
Immunotherapy	Major topic
Proto-Oncogene Proteins c-ret	Major topic
Immune Checkpoint Inhibitors	Major topic
Humans
Proto-Oncogene Mas
Mutation
Female
Male
Biomarkers, Tumor

Source PubMed

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes it	Agency	Country	NIH project	Stated by
82373367	National Natural Science Foundation of China			PubMed
2025YJRHPD05	Innovation of Science and Technology			PubMed

Source PubMed

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References38

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

Order	PMID	Title	Journal	Year	In Papers	Source
1	25,409,260	Genetic basis for clinical response to CTLA-4 blockade in melanoma.	N Engl J Med	2014	https://conductscience.org/library/papers/25409260	PubMed
2	29,033,130	Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab.	Cell	2017	https://conductscience.org/library/papers/29033130	PubMed
3	26,359,337	Genomic correlates of response to CTLA-4 blockade in metastatic melanoma.	Science	2015	https://conductscience.org/library/papers/26359337	PubMed
4	28,931,560	RET-mediated modulation of tumor microenvironment and immune response in multiple endocrine neoplasia type 2 (MEN2).	Endocr Relat Cancer	2018	https://conductscience.org/library/papers/28931560	PubMed
5	32,728,392	Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials.	Ther Adv Med Oncol	2020	https://conductscience.org/library/papers/32728392	PubMed
6	24,561,444	RET revisited: expanding the oncogenic portfolio.	Nat Rev Cancer	2014	https://conductscience.org/library/papers/24561444	PubMed
7	31,940,268	Top 10 Challenges in Cancer Immunotherapy.	Immunity	2020	https://conductscience.org/library/papers/31940268	PubMed
8	36,639,452	At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC.	Nat Rev Clin Oncol	2023	https://conductscience.org/library/papers/36639452	PubMed
9	22,016,822	Dissection of the RET/β-catenin interaction in the TPC1 thyroid cancer cell line.	Am J Cancer Res	2011	https://conductscience.org/library/papers/22016822	PubMed
10	32,025,018	The repertoire of mutational signatures in human cancer.	Nature	2020	https://conductscience.org/library/papers/32025018	PubMed

1 to 10 of 38

See all 38 references

Cited by0

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 0 citations.

None in this release.

Genes0

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

None in this release.

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41701164

GET https://conductscience.org/api/papers/v1/41701164/references?page=2

API reference For AI assistants